Senti Biosciences, Inc. (SNTI)
(Delayed Data from NSDQ)
$2.27 USD
-0.08 (-3.40%)
Updated Jul 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Senti Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 36 | 99 | 1 | -99,999 | -99,999 |
Receivables | 18 | 1 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 18 | 3 | 0 | NA | NA |
Total Current Assets | 71 | 103 | 1 | NA | NA |
Net Property & Equipment | 25 | 56 | 0 | NA | NA |
Investments & Advances | 0 | 0 | 230 | NA | NA |
Other Non-Current Assets | 1 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 6 | 4 | 0 | NA | NA |
Total Assets | 119 | 181 | 231 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 1 | 2 | 0 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 6 | 13 | 3 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 1 | 1 | 0 | NA | NA |
Total Current Liabilities | 13 | 18 | 3 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 7 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 6 | 0 | 230 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 53 | 54 | 240 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 0 | 0 | 0 | NA | NA |
Capital Surplus | 311 | 301 | 0 | NA | NA |
Retained Earnings | -244 | -173 | -9 | NA | NA |
Other Equity | 0 | 0 | 0 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 67 | 127 | -9 | NA | NA |
Total Liabilities & Shareholder's Equity | 119 | 181 | 231 | NA | NA |
Total Common Equity | 67 | 127 | -9 | 0 | 0 |
Shares Outstanding | 4.40 | 4.30 | 2.30 | NA | NA |
Book Value Per Share | 15.21 | 29.60 | -3.86 | 0.00 | 0.00 |
Fiscal Year End for Senti Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 24 | 36 | 39 | 60 |
Receivables | NA | 18 | 18 | 19 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 14 | 18 | 21 | 3 |
Total Current Assets | NA | 56 | 71 | 79 | 63 |
Net Property & Equipment | NA | 24 | 25 | 26 | 59 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 1 | 1 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 6 | 6 | 8 | 4 |
Total Assets | NA | 102 | 119 | 132 | 144 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 6 | 4 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 0 |
Total Current Liabilities | NA | 10 | 13 | 10 | 10 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 6 | 4 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 46 | 53 | 49 | 46 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 313 | 311 | 309 | 308 |
Retained Earnings | NA | -256 | -244 | -226 | -211 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 56 | 67 | 83 | 97 |
Total Liabilities & Shareholder's Equity | NA | 102 | 119 | 132 | 144 |
Total Common Equity | 0 | 56 | 67 | 83 | 97 |
Shares Outstanding | 4.50 | 4.50 | 4.40 | 4.40 | 4.40 |
Book Value Per Share | 0.00 | 12.46 | 15.21 | 18.85 | 22.14 |